{"brief_title": "A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV", "brief_summary": "To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.", "detailed_description": "Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.", "condition": ["HIV Infections", "Chickenpox"], "intervention_type": ["Drug"], "intervention_name": ["Sorivudine"], "criteria": "Inclusion Criteria Patients must have: - HIV infection. - Cutaneous, visceral, or ocular varicella-zoster viral infection. - Refractory or intolerant to acyclovir or foscarnet therapy. - Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Inability to take oral capsules or tolerate liquids. Concurrent Medication: Excluded: - 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid. Patients with the following prior condition are excluded: History of immediate hypersensitivity to nucleoside analogues. Prior Medication: Excluded: - 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry. Required: - Prior acyclovir or foscarnet.", "gender": "All", "minimum_age": "2 Years", "maximum_age": "17 Years", "healthy_volunteers": "No", "keyword": "Chickenpox", "mesh_term": ["HIV Infections", "Chickenpox", "Virus Diseases", "Sorivudine"], "id": "NCT00002358"}